RecruitingPhase 3NCT06262594
Lemborexant Treatment of Insomnia Linked to Epilepsy
Sponsor
University of Manitoba
Enrollment
26 participants
Start Date
Oct 29, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Sleep-related focal epilepsy
- Contraception
Exclusion Criteria10
- Changes in antiseizure medication 1 month before study protocol or during study protocol
- Concomitant medications per SUNRISE1
- Individuals with hepatic impairment
- Female participants who are pregnant or breastfeeding
- Individuals with compromised respiratory function
- Individuals with a history of complex sleep-related behaviour
- Individuals with rare hereditary diseases of galactose intolerance such as galactosemia or glucose-galactose malabsorption
- Individuals with a history of dependence or tolerance - abuse, dependence, rebound insomnia
- Individuals with psychiatric disorders with abnormal thinking and behavioural changes, depression, or suicidal ideation
- Individuals with a diagnosis of narcolepsy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLemborexant
Drug is administered
DRUGPlacebo
Drug is administered
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06262594
Related Trials
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
NCT021079891 location
Tumor Related Epilepsy
NCT026393251 location
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
NCT025318801 location
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT075638813 locations
Sleep Trial to Prevent Alzheimer's Disease
NCT046295471 location